Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase…
Biotechnology
US, Cambridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Prime Medicine, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | - | -4.180 | - | 4 | - | -380 | - | 3 | - | 3 | - | 3 |
| 2023 | -1.2500 | -1.898 | 0 | 4 | -121 | -168 | -110 | 3 | -116 | 3 | 29 | 4 |
| 2024 | -2.1800 | -1.701 | 0 | 9 | -198 | -150 | -193 | 6 | -334 | 6 | 38 | 8 |
| 2025 | - | -1.343 | - | 14 | - | -123 | - | 10 | - | 10 | - | 13 |
| 2026 | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |